The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group

American Journal of Hematology

Volumn 89, Issue 1, 2014, Pages 34-40

  Terpos, Evangelos ^a   Christoulas, Dimitrios ^b   Kastritis, Efstathios ^a   Katodritou, Eirini ^c   Papatheodorou, Athanasios ^b   Pouli, Anastasia ^d   Kyrtsonis, Marie Christine ^a   Michalis, Eurydiki ^e   Papanikolaou, Xenophon ^f   Gkotzamanidou, Maria ^a   Koulieris, Efstathios ^a   Gavriatopoulou, Maria ^a   Zervas, Konstantinos ^c   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^c THEAGENIO CANCER HOSPITAL   (Greece)

^d St Savvas Oncology Hospital   (Greece)

^e IASO GENERAL HOSPITAL   (Greece)

^f METAXA CANCER HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARBOXY TERMINAL TELOPEPTIDE; DEXAMETHASONE; DICKKOPF 1 PROTEIN; LENALIDOMIDE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; AGED; ARTICLE; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEUTROPENIA; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPINE FRACTURE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BONE REMODELING; BONE RESORPTION; DEXAMETHASONE; FEMALE; GREECE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM GRADING; NEOPLASM STAGING; OSTEOGENESIS; RECURRENCE; RETROSPECTIVE STUDIES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84892897649     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23577     Document Type: Article

References (34)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111:2962-2972.
2. Kastritis E, Zervas K, Symeonidis A, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): An analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009;23:1152-1157.
3. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-2132.
4. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-2142.
5. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33.
6. Terpos E, Politou M, Rahemtulla A. New insights into the pathophysiology and management of bone disease in multiple myeloma. Br J Haematol 2003;123:758-769.
7. Roodman GD. Pathogenesis of myeloma bone disease. Leukemia 2009;23:435-441.
8. Sezer O, Heider U, Zavrski I, et al. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003;101:2094-2098.
9. Vanderkerken K, De Leenheer E, Shipman C, et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003;63:287-289.
10. Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor kappa-B ligand-osteoprotegerin ratio predicts survival in multiple myeloma: Proposal for a novel prognostic index. Blood 2003;102:1064-1069.
11. Grimaud E, Soubigou L, Couillaud S, et al. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 2003;163:2021-2031.
12. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-2494.
13. Politou MC, Heath DJ, Rahemtulla A, et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 2006;119:1728-1731.
14. Kaiser M, Mieth M, Liebisch P, et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 2008;80:490-494.
15. Terpos E, Dimopoulos MA, Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007;21:1875-1884.
16. Terpos E, Heath DJ, Rahemtulla A, et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006;135:688-692.
17. Zangari M, Yaccoby S, Pappas L, et al. A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica 2011;96:333-336.
18. Delforge M, Terpos E, Richardson PG, et al. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. Eur J Haematol 2011;86:372-384.
19. Anderson G, Gries M, Kurihara N, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006;107:3098-3105.
20. Terpos E, Mihou D, Szydlo R, et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 2005;19:1969-1976.
21. Tosi P, Zamagni E, Cellini C, et al. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. Eur J Haematol 2006;76:399-404.
22. Breitkreutz I, Raab MS, Vallet S, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008;22:1925-1932.
23. Tsuda H, Yamasaki H, Tsuji T, Yokoo E. Therapy with lenalidomide plus dexamethasone-induced bone formation in a patient with refractory multiple myeloma. Int J Hematol 2012;95:706-710.
24. Dimopoulos MA, Kastritis E, Christoulas D, et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: Prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 2010;24:1769-1778.
25. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473.
26. Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009;23:2147-2152.
27. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366:1759-1769.
28. Hozumi A, Osaki M, Goto H, et al. Bone marrow adipocytes support dexamethasone-induced osteoclast differentiation. Biochem Biophys Res Commun 2009;382:780-784.
29. Viereck V, Emons G, Lauck V, et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002;291:680-686.
30. Koch FP, Merkel C, Ziebart T, et al. Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro. Clin Oral Investig 2012;16:79-86.
31. Burington B, Barlogie B, Zhan F, et al. Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma. Clin Cancer Res 2008;14:4821-4829.
32. Tian E, Qiang Y, Barlogie B, Shaughnessy JD Jr. DKK1 is an immediate early gene in multiple myeloma cells modulated by cell density and IL-6. Blood 2010;116 (ASH abstracts volume):802-803.
33. Ohnaka K, Taniguchi H, Kawate H, et al. Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: Novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun 2004;318:259-264.
34. Terpos E, Christoulas D, Kokkoris P, et al. Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. Ann Oncol 2010;21:1561-1562.